Sankhala K[au] - Search Results

Year	Number of Results
2007	1
2008	1
2009	7
2010	1
2011	6
2012	3
2013	3
2014	6
2015	2
2016	1
2017	3
2018	2
2019	2
2020	2
2021	3
2022	2
2024	1

1

Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.

Kesari S, Wagle N, Carrillo JA, Sharma A, Nguyen M, Truong J, Gill JM, Nersesian R, Nomura N, Rahbarlayegh E, Barkhoudarian G, Sivakumar W, Kelly DF, Krauss H, Bustos MA, Hoon DSB, Anker L, Singh AS, Sankhala KK, Juarez TM. Kesari S, et al. Among authors: sankhala kk. Clin Cancer Res. 2024 Jan 17;30(2):323-333. doi: 10.1158/1078-0432.CCR-23-2317. Clin Cancer Res. 2024. PMID: 38047868

2

Heat shock proteins: a potential anticancer target.

Sankhala KK, Mita MM, Mita AC, Takimoto CH. Sankhala KK, et al. Curr Drug Targets. 2011 Dec;12(14):2001-8. doi: 10.2174/138945011798829339. Curr Drug Targets. 2011. PMID: 21777196 Review.

3

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.

Gordon EM, Sankhala KK, Chawla N, Chawla SP. Gordon EM, et al. Among authors: sankhala kk. Adv Ther. 2016 Jul;33(7):1055-71. doi: 10.1007/s12325-016-0344-3. Epub 2016 May 27. Adv Ther. 2016. PMID: 27234989 Free PMC article. Review.

4

Targeting the mTOR pathway using deforolimus in cancer therapy.

Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM. Mahalingam D, et al. Among authors: sankhala k. Future Oncol. 2009 Apr;5(3):291-303. doi: 10.2217/fon.09.9. Future Oncol. 2009. PMID: 19374536 Review.

5

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.

Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Mita M, et al. Among authors: sankhala k. Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54. doi: 10.1517/13543780802556485. Expert Opin Investig Drugs. 2008. PMID: 19012509 Review.

6

Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.

Sankhala KK. Sankhala KK. Expert Opin Investig Drugs. 2017 Apr;26(4):427-443. doi: 10.1080/13543784.2017.1303045. Epub 2017 Mar 20. Expert Opin Investig Drugs. 2017. PMID: 28267385 Review.

7

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. Sankhala K, et al. Target Oncol. 2009 Apr;4(2):135-42. doi: 10.1007/s11523-009-0107-z. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381454 Review.

8

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.

Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP. Sankhala KK, et al. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1607-14. doi: 10.1517/17425250903451675. Expert Opin Drug Metab Toxicol. 2009. PMID: 19929449 Review.

9

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M. Vemulapalli S, et al. Among authors: sankhala k. Target Oncol. 2011 Mar;6(1):29-39. doi: 10.1007/s11523-011-0179-4. Epub 2011 Apr 28. Target Oncol. 2011. PMID: 21533543 Review.

10

Combined Central Retinal Artery and Vein Occlusion with Ischemic Optic Neuropathy After COVID-19 Vaccination.

Lee S, Sankhala KK, Bose S, Gallemore RP. Lee S, et al. Among authors: sankhala kk. Int Med Case Rep J. 2022 Jan 16;15:7-14. doi: 10.2147/IMCRJ.S328931. eCollection 2022. Int Med Case Rep J. 2022. PMID: 35079224 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year